Three pharma stocks are in focus after a series of positive regulatory and international developments. Business Today’s Neetu Chandra Sharma explains why Gland Pharma, Caplin Point and Nephrocare Health Services are seeing renewed investor interest. Gland Pharma completed a US FDA inspection with zero observations, while Caplin Point received confirmation from Colombia’s drug regulator for one of its facilities. Nephrocare Health Services is expanding its international presence through the acquisition of a dialysis centre in Kazakhstan. While these developments are positive, the stocks have already delivered strong gains in 2026. Investors will now closely track earnings, sales growth, profits and valuations to assess their future outlook.
IFCI, NIACL stocks jump up to 14%; NSE IPO buzz lifts focus: Analysts share outlook
After TCS, Wipro installs employee productivity tracker: Inactive days could trigger leave
SBI customers alert! UPI to go offline on September 4: Check timing, duration and alternative
Russia Returns To G20 Talks As U.S. Engages Moscow, Europe Pushes Back
Pranav Constructions IPO opens on Sept 7: Check price band, issue size and other key details IFCI, NIACL stocks jump up to 14%; NSE IPO buzz lifts focus: Analysts share outlookPranav Constructions IPO opens on Sept 7: Check price band, issue size and other key details 
Ujjivan SFB stock: Brokerages share price targets as near-term uncertainty likely to persist 
BEL, AEL, ICICI Bank, Eternal, BSE, Dixon Tech, Coforge, RBL Bank: MOFSL's top picks 
GPT Infraprojects shares rise over 9% on fresh order win, check details Russia Returns To G20 Talks As U.S. Engages Moscow, Europe Pushes Back
Deepa Jewellery IPO: Why This B2B Player Is Raising Funds Amid Rising Organised Retail Demand
India’s 7.8% Q1 GDP Under Scrutiny: Subhash Garg Vs Sanjeev Sanyal On The Numbers
Piyush Goyal Says India Could Become The World’s Data Centre Hub With $200 Billion Investment
Meet John Ternus: The Engineer Taking Over Apple After Tim Cook’s 15-Year Reign
